BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2026 9:34:58 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-01-28 00:46 |
|
Peer-Review Started |
|
2026-01-28 00:46 |
|
First Decision by Editorial Office Director |
|
2026-02-14 07:50 |
|
Return for Revision |
|
2026-02-14 07:50 |
|
Revised |
|
2026-02-15 03:04 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-08 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-08 08:04 |
|
Articles in Press |
|
2026-04-08 08:04 |
|
Edit the Manuscript by Language Editor |
|
2026-04-09 13:54 |
|
Typeset the Manuscript |
|
2026-06-22 07:20 |
|
Publish the Manuscript Online |
|
2026-07-14 09:34 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chuong Dinh Nguyen and Luan Minh Dang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Luan Minh Dang, Lecturer, MD, Department of Gastroenterology, University Medical Center, No. 215 Hong Bang Street, Cho Lon Ward, Ho Chi Minh City 700000, Viet Nam. luan.dm@umc.edu.vn |
| Key Words |
Biosimilars; Inflammatory bowel disease; Nocebo effect; Biologic switching; Health equity |
| Core Tip |
Biosimilars in inflammatory bowel disease have moved beyond a narrow question of pharmacological equivalence. Although current evidence supports their efficacy, safety, and use across multiple clinical scenarios, adoption remains limited by nocebo-related discontinuation, physician hesitation, and system-level implementation barriers. This opinion review synthesizes current evidence, examines persistent controversies, and proposes a pragmatic 5-step framework for biosimilar initiation or switching in routine care. It also highlights the special challenges of resource-limited settings and introduces the concept of a “nocebo-prone environment” as a practical lens for understanding barriers to equitable biosimilar integration. |
| Publish Date |
2026-07-14 09:34 |
| Citation |
Nguyen CD, Dang LM. Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation. World J Gastroenterol 2026; 32(28): 119462
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i28/119462.htm |
| DOI |
https://doi.org/10.3748/wjg.119462 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
